Why Women Show Higher Amyloid Burden: New Evidence on Sex, Race, and APOE ε4 Interactions in Alzheimer’s Pathology
Posted inNeurology news Pathology & Lab Medicine/Bệnh học

Why Women Show Higher Amyloid Burden: New Evidence on Sex, Race, and APOE ε4 Interactions in Alzheimer’s Pathology

A Brazilian autopsy study of 2,268 individuals reveals that female sex, APOE ε4 status, and African ancestry jointly influence amyloid pathology. Women showed 65% higher adjusted odds of neuritic plaques, and protective effects against amyloid in Black individuals were attenuated by APOE ε4 carriage, highlighting critical disparities in Alzheimer's disease pathogenesis.
Home-Based Gamma tACS Improves Cognitive Function and Daily Living in Alzheimer Disease: Results from a Randomized Clinical Trial
Posted inNeurology news

Home-Based Gamma tACS Improves Cognitive Function and Daily Living in Alzheimer Disease: Results from a Randomized Clinical Trial

A randomized clinical trial demonstrates that home-based gamma transcranial alternating current stimulation (tACS) over the precuneus safely improves cognitive outcomes and activities of daily living in patients with prodromal and mild Alzheimer disease, supported by neurophysiological evidence of brain engagement.
White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances
Posted inClinical Updates Neurology news Radiology

White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances

This review synthesizes recent large-scale multi-cohort studies revealing white matter microstructural abnormalities—especially free water increases—in limbic tracts as critical markers of cognitive decline in aging and Alzheimer's disease, emphasizing integrated biomarker approaches.
Lower Posttreatment Amyloid Predicts Slower Clinical Decline and Reduced Tau/Glial Biomarkers After Donanemab: Secondary Analysis of TRAILBLAZER‑ALZ 2
Posted inNeurology news

Lower Posttreatment Amyloid Predicts Slower Clinical Decline and Reduced Tau/Glial Biomarkers After Donanemab: Secondary Analysis of TRAILBLAZER‑ALZ 2

A secondary analysis of TRAILBLAZER‑ALZ 2 found that lower posttreatment amyloid plaque levels after donanemab correlate strongly with less clinical decline and reductions in plasma p‑tau217, p‑tau181, and GFAP over 76 weeks, supporting plaque removal as a likely mechanism of benefit.